2017
Epigenetic Regulations in the Pathogenesis of HCC and the Clinical Application
Puszyk W, Robertson K, Liu C. Epigenetic Regulations in the Pathogenesis of HCC and the Clinical Application. 2017, 69-93. DOI: 10.1007/978-3-319-68082-8_5.Peer-Reviewed Original ResearchNonalcoholic fatty liver diseaseDevelopment of hepatocellular carcinomaHepatocellular carcinoma casesHepatocellular carcinomaHepatitis B virusHepatitis C virusRisk factorsChronic infectionNonalcoholic steatohepatitisViral hepatocellular carcinomaChronic cigarette smokingIndependent risk factorPathogenesis of hepatocellular carcinomaConsumption of excess caloriesLiver cancer casesFatty liver diseaseProgress to nonalcoholic steatohepatitisExposure to environmental factorsHCC casesLiver malignanciesConsumption of alcoholCancer casesB virusC virusLiver disease
2009
Betaine for nonalcoholic fatty liver disease: Results of a randomized placebo‐controlled trial
Abdelmalek M, Sanderson S, Angulo P, Soldevila‐Pico C, Liu C, Peter J, Keach J, Cave M, Chen T, McClain C, Lindor K. Betaine for nonalcoholic fatty liver disease: Results of a randomized placebo‐controlled trial. Hepatology 2009, 50: 1818-1826. PMID: 19824078, DOI: 10.1002/hep.23239.Peer-Reviewed Original ResearchConceptsNonalcoholic steatohepatitisBetaine therapyHepatic steatosisAnimal studiesNonalcoholic fatty liver disease activity scoreBiopsy-proven nonalcoholic steatohepatitisRandomized placebo-controlled trialNonalcoholic fatty liver diseaseRandomized placebo-controlled studyPosttreatment liver biopsiesDisease Activity ScorePlacebo-controlled studyPlacebo-controlled trialFatty liver diseaseElevation of insulinNovel therapeutic optionsSecond hit mechanismsOral betaineWilcoxon rank testNASH patientsLiver biopsyActivity scoreLiver diseaseRemethylation of homocysteineSteatosis grade